Korlym (Mifepristone) — Medicare Part D spending
Corcept Therape · Rank #204 by total Part D spend · CMS data year 2023
Medicare Part D spent $228,814,734 on Korlym (Mifepristone) in 2023, the #204 drug by total Part D spending out of 3,598 drugs. That worked out to about $632.17 per dosage unit, $32,895 per claim and $216,067 per beneficiary, across 6,956 claims for 1,059 beneficiaries. Average spending per dosage unit rose +9.0% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Korlym (Mifepristone) spending at a glance (2023)
| Metric | Korlym (Mifepristone) |
|---|---|
| Total Part D spending (2023) | $228,814,734 |
| Total spending (2022) | $187,312,598 |
| Year-over-year change in total spending | +22.2% |
| Average spending per dosage unit (2023) | $632.17 |
| Change in spend per dosage unit (YoY) | +9.0% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +6.7% |
| Average spending per claim (2023) | $32,895 |
| Average spending per beneficiary (2023) | $216,067 |
| Total claims (2023) | 6,956 |
| Beneficiaries (2023) | 1,059 |
| Total dosage units (2023) | 361,950 |
| Manufacturer(s) | Corcept Therape |
| National rank by total spend (of 3,598 drugs) | #204 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $187,312,598 | $228,814,734 | +22.2% |
| Avg spend per dosage unit | $579.93 | $632.17 | +9.0% |
| Avg spend per claim | $30,808 | $32,895 | — |
| Avg spend per beneficiary | $221,410 | $216,067 | — |
| Total claims | 6,080 | 6,956 | — |
| Beneficiaries | 846 | 1,059 | — |
How Korlym compares with nearby drugs
Drugs with total Part D spending closest to Korlym (Mifepristone):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Korlym (Mifepristone) (this drug, #204) | $228,814,734 | $632.17 | +9.0% |
| Emgality Pen (Galcanezumab-Gnlm) (#202) | $229,252,597 | $716.06 | +3.1% |
| Icosapent Ethyl (#203) | $228,873,224 | $2.04 | -4.3% |
| Humalog Kwikpen U-200 (Insulin Lispro) (#205) | $224,440,404 | $73.76 | +0.8% |
| Soliris (Eculizumab) (#206) | $223,473,529 | $228.56 | +0.9% |
| Gammaked (Immune Globul G/Gly/IgA Avg 46) (#207) | $220,007,929 | $18.74 | +10.1% |
Frequently asked questions
How much does Medicare Part D spend on Korlym?
Medicare Part D spent $228,814,734 on Korlym (Mifepristone) in 2023 (the latest CMS data year), across 6,956 claims for 1,059 beneficiaries. That ranks #204 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Korlym?
In 2023, the weighted average Medicare Part D spending per dosage unit for Korlym (Mifepristone) was $632.17. Compared with 2022 it rose +9.0%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Korlym?
CMS attributes Korlym (Mifepristone) to Corcept Therape in the 2023 Part D spending file. Average spending per claim was $32,895 and per beneficiary $216,067.
Is the Korlym figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20